低密度脂蛋白与受体结合减少作为原发性中度高胆固醇血症病因的体内证据。
In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia.
作者信息
Vega G L, Grundy S M
出版信息
J Clin Invest. 1986 Nov;78(5):1410-4. doi: 10.1172/JCI112729.
Abstract
The causes of primary moderate hypercholesterolemia are not understood, but some patients have reduced fractional clearance rates (FCRs) for low density lipoproteins (LDL). This could be due to either decreased activity of LDL receptors or to a defect in structure (or composition) of LDL that reduces its affinity for receptors. To distinguish between these causes, simultaneous turnover rates of autologous and normal homologous LDL were determined in 15 patients with primary moderate hypercholesterolemia. In 10, turnover rates of both types of LDL were indistinguishable, which indicated that autologous LDL was cleared as efficiently as normal homologous LDL. In five others, FCRs for autologous LDL were significantly lower than for homologous LDL. Two of the latter five were treated with mevinolin, and although FCRs for both types of LDL rose during treatment, differences in FCRs between the two types of LDL persisted. In these five patients, autologous LDL appeared to be a poor ligand for LDL receptors.
摘要
原发性中度高胆固醇血症的病因尚不清楚，但一些患者的低密度脂蛋白（LDL）分数清除率（FCR）降低。这可能是由于LDL受体活性降低，或者是由于LDL结构（或组成）缺陷导致其对受体的亲和力降低。为了区分这些原因，对15例原发性中度高胆固醇血症患者测定了自体LDL和正常同源LDL的同时转换率。在10例患者中，两种类型LDL的转换率无明显差异，这表明自体LDL与正常同源LDL的清除效率相同。在另外5例患者中，自体LDL的FCR显著低于同源LDL。后5例中的2例接受了美伐他汀治疗，尽管治疗期间两种类型LDL的FCR均升高，但两种类型LDL的FCR差异仍然存在。在这5例患者中，自体LDL似乎是LDL受体的不良配体。
相似文献
1
In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia.低密度脂蛋白与受体结合减少作为原发性中度高胆固醇血症病因的体内证据。
J Clin Invest. 1986 Nov;78(5):1410-4. doi: 10.1172/JCI112729.
2
Coinheritance of two mild defects in low density lipoprotein receptor function produces severe hypercholesterolemia.低密度脂蛋白受体功能的两种轻度缺陷共同遗传会导致严重的高胆固醇血症。
J Clin Endocrinol Metab. 1991 Jan;72(1):179-87. doi: 10.1210/jcem-72-1-179.
3
[Catabolism of low-density lipoproteins via receptors and its regulation].[通过受体的低密度脂蛋白分解代谢及其调节]
Ann Biol Clin (Paris). 1986;44(5):545-50.
4
Metabolic basis of primary hypercholesterolemia.原发性高胆固醇血症的代谢基础
Circulation. 1991 Jul;84(1):118-28. doi: 10.1161/01.cir.84.1.118.
5
Changes in ultracentrifugally separated plasma lipoprotein subfractions in patients with polygenic hypercholesterolemia, familial combined hyperlipoproteinemia, and familial hypercholesterolemia after treatment with atorvastatin.阿托伐他汀治疗后多基因高胆固醇血症、家族性混合性高脂血症和家族性高胆固醇血症患者超离心分离的血浆脂蛋白亚组分的变化。
J Clin Lipidol. 2015 Mar-Apr;9(2):210-6. doi: 10.1016/j.jacl.2014.12.007. Epub 2014 Dec 16.
6
Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.美伐他汀对原发性中度高胆固醇血症患者低密度脂蛋白代谢的影响。
J Lipid Res. 1985 Dec;26(12):1464-75.
7
Studies on mechanisms for enhanced clearance of low-density lipoproteins in patients with primary hypertriglyceridaemia.原发性高甘油三酯血症患者低密度脂蛋白清除增强机制的研究。
J Intern Med. 1989 Jul;226(1):5-15. doi: 10.1111/j.1365-2796.1989.tb01347.x.
8
Clinical studies in a kindred with a kinetic LDL receptor mutation causing familial hypercholesterolemia.对一个因动力学低密度脂蛋白受体突变导致家族性高胆固醇血症的家族进行的临床研究。
Am J Med Genet. 1985 Nov;22(3):593-8. doi: 10.1002/ajmg.1320220318.
9
Genetics and kinetics of familial hypercholesterolemia, with the special focus on FH-(Marburg) p.W556R.家族性高胆固醇血症的遗传学与动力学，特别关注FH-（马尔堡）p.W556R
Atheroscler Suppl. 2009 Dec 29;10(5):5-11. doi: 10.1016/S1567-5688(09)71802-1.
10
Mechanisms of primary hypercholesterolemia in humans.人类原发性高胆固醇血症的机制。
Am Heart J. 1987 Feb;113(2 Pt 2):493-502. doi: 10.1016/0002-8703(87)90620-x.
引用本文的文献
1
Hepatic Lipoprotein Metabolism: Current and Future In Vitro Cell-Based Systems.肝脏脂蛋白代谢：当前和未来基于细胞的体外系统
Biomolecules. 2025 Jul 2;15(7):956. doi: 10.3390/biom15070956.
2
Genetic Determinants of the Familial Hypercholesterolaemia Phenotype.家族性高胆固醇血症表型的遗传决定因素
Ann Hum Genet. 2025 Sep;89(5):293-304. doi: 10.1111/ahg.12594. Epub 2025 Apr 2.
3
Familial Hypercholesterolemia: A Literature Review of the Pathophysiology and Current and Novel Treatments.家族性高胆固醇血症：病理生理学以及当前和新型治疗方法的文献综述
Cureus. 2023 Nov 20;15(11):e49121. doi: 10.7759/cureus.49121. eCollection 2023 Nov.
4
Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetics and Biochemical Parameters.家族性高胆固醇血症：1236名就诊于捷克脂质诊所患者的真实世界数据。50多年经验的回顾性分析。第一部分：遗传学和生化参数。
Front Genet. 2022 Feb 28;13:849008. doi: 10.3389/fgene.2022.849008. eCollection 2022.
5
Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation.在具有低密度脂蛋白受体突变和PCSK9 V4I突变的双杂合子家族性高胆固醇血症中，PCSK9抗体与瑞舒伐他汀对冠状动脉斑块的消退作用
Intern Med. 2018;57(24):3551-3557. doi: 10.2169/internalmedicine.1060-18. Epub 2018 Dec 15.
6
Interpreting the Mechanism of APOE (p.Leu167del) Mutation in the Incidence of Familial Hypercholesterolemia; An In-silico Approach.解读APOE（p.Leu167del）突变在家族性高胆固醇血症发病中的机制；一种计算机模拟方法。
Open Cardiovasc Med J. 2017 Sep 14;11:84-93. doi: 10.2174/1874192401711010084. eCollection 2017.
7
Evaluation of reported pathogenic variants and their frequencies in a Japanese population based on a whole-genome reference panel of 2049 individuals.基于 2049 人的全基因组参考面板评估日本人群中报道的致病性变异体及其频率。
J Hum Genet. 2018 Feb;63(2):213-230. doi: 10.1038/s10038-017-0347-1. Epub 2017 Dec 1.
8
The Spectrum of Familial Hypercholesterolemia (FH) in Saudi Arabia: Prime Time for Patient FH Registry.沙特阿拉伯家族性高胆固醇血症（FH）的谱系：建立患者FH登记册的黄金时机。
Open Cardiovasc Med J. 2017 Jul 26;11:66-75. doi: 10.2174/1874192401711010066. eCollection 2017.
9
The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations.家族性高胆固醇血症的遗传基础：遗传、连锁与突变
Appl Clin Genet. 2010 Aug 5;3:53-64. doi: 10.2147/tacg.s8285. Print 2010.
10
Novel gene-by-environment interactions: APOB and NPC1L1 variants affect the relationship between dietary and total plasma cholesterol.新型基因-环境交互作用：APOB 和 NPC1L1 变异影响饮食和总血浆胆固醇之间的关系。
J Lipid Res. 2013 May;54(5):1512-20. doi: 10.1194/jlr.P035238. Epub 2013 Mar 11.
本文引用的文献
1
The theory of tracer experiments with 131I-labelled plasma proteins.用131I标记血浆蛋白的示踪实验理论
Phys Med Biol. 1957 Jul;2(1):36-53. doi: 10.1088/0031-9155/2/1/305.
2
Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study.北美特定人群中的脂蛋白胆固醇分布：脂质研究诊所项目患病率研究
Circulation. 1980 Feb;61(2):302-15. doi: 10.1161/01.cir.61.2.302.
3
Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms.人载脂蛋白E的异质性。载脂蛋白E同工型氨基酸序列中的半胱氨酸-精氨酸互换。
J Biol Chem. 1981 Sep 10;256(17):9077-83.
4
Influence of polyunsaturated fats on composition of plasma lipoproteins and apolipoproteins.多不饱和脂肪对血浆脂蛋白和载脂蛋白组成的影响。
J Lipid Res. 1982 Aug;23(6):811-22.
5
Increased low density lipoprotein production associated with obesity.与肥胖相关的低密度脂蛋白生成增加。
Arteriosclerosis. 1983 Mar-Apr;3(2):170-7. doi: 10.1161/01.atv.3.2.170.
6
Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.美维诺林和考来替泊可刺激家族性高胆固醇血症杂合子患者血浆中低密度脂蛋白通过受体介导的清除。
Proc Natl Acad Sci U S A. 1983 Jul;80(13):4124-8. doi: 10.1073/pnas.80.13.4124.
7
The human apolipoprotein B-100 gene: a highly polymorphic gene that maps to the short arm of chromosome 2.人类载脂蛋白B-100基因：一个高度多态性的基因，定位于2号染色体短臂。
Biochem Biophys Res Commun. 1985 Nov 27;133(1):248-55. doi: 10.1016/0006-291x(85)91868-6.
8
Kinetic mechanisms determining variability in low density lipoprotein levels and rise with age.决定低密度脂蛋白水平变异性及随年龄增长而升高的动力学机制。
Arteriosclerosis. 1985 Nov-Dec;5(6):623-30. doi: 10.1161/01.atv.5.6.623.
9
Familial hypercholesterolemia with "normal" cholesterol in obligate heterozygotes.纯合子家族性高胆固醇血症患者胆固醇水平“正常”的情况
Am J Med Genet. 1985 Nov;22(3):585-91. doi: 10.1002/ajmg.1320220317.
10
A partial cDNA clone for human apolipoprotein B.人载脂蛋白B的部分互补DNA克隆。
Proc Natl Acad Sci U S A. 1985 Aug;82(15):4983-6. doi: 10.1073/pnas.82.15.4983.
Zotero 插件